Medulloblastoma - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Medulloblastoma - Pipeline Review, H1 2016

Medulloblastoma - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Medulloblastoma - Pipeline Review, H1 2016
Published Jun 08, 2016
96 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Medulloblastoma - Pipeline Review, H1 2016, provides an overview of the Medulloblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
- The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Medulloblastoma therapeutics and enlists all their major and minor projects
- The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Medulloblastoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
-

  
Source:
Document ID
GMDHC8191IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Medulloblastoma Overview91
Therapeutics Development102
  Pipeline Products for Medulloblastoma Overview101
  Pipeline Products for Medulloblastoma Comparative Analysis111
Medulloblastoma Therapeutics under Development by Companies121
Medulloblastoma Therapeutics under Investigation by Universities/Institutes131
Medulloblastoma Pipeline Products Glance143
  Clinical Stage Products141
  Early Stage Products151
  Unknown Stage Products161
Medulloblastoma Products under Development by Companies171
Medulloblastoma Products under Investigation by Universities/Institutes181
Medulloblastoma Companies Involved in Therapeutics Development1912
  Bayer AG191
  DelMar Pharmaceuticals, Inc.201
  Ignyta, Inc.211
  Lipocure Ltd.221
  MacroGenics, Inc.231
  Medicenna Therapeutics, Inc.241
  MEI Pharma, Inc.251
  Novartis AG261
  Novogen Limited271
  Progenics Pharmaceuticals, Inc.281
  Stemline Therapeutics, Inc.291
  Takeda Pharmaceutical Company Limited301
Medulloblastoma Therapeutics Assessment3110
  Assessment by Monotherapy Products311
  Assessment by Combination Products321
  Assessment by Target332
  Assessment by Mechanism of Action352
  Assessment by Route of Administration372
  Assessment by Molecule Type392
Drug Profiles4130
  (topotecan hydrochloride + vincristine sulfate) - Drug Profile411
    Product Description411
    Mechanism of Action411
    R&D Progress411
  Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  dianhydrogalactitol - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress433
  Edotreotide Labeled Yttrium 90 - Drug Profile461
    Product Description461
    Mechanism of Action461
    R&D Progress462
  irinotecan hydrochloride + TBio-02 - Drug Profile481
    Product Description481
    Mechanism of Action481
    R&D Progress482
  LEQ-506 - Drug Profile501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  MDNA-55 - Drug Profile511
    Product Description511
    Mechanism of Action511
    R&D Progress511
  Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma and Medulloblastoma - Drug Profile521
    Product Description521
    Mechanism of Action521
    R&D Progress521
  Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile531
    Product Description531
    Mechanism of Action531
    R&D Progress531
  nifurtimox - Drug Profile541
    Product Description541
    Mechanism of Action541
    R&D Progress541
  nifurtimox SR - Drug Profile551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  p28 - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress562
  pracinostat - Drug Profile581
    Product Description581
    Mechanism of Action581
    R&D Progress582
  siomycin A - Drug Profile601
    Product Description601
    Mechanism of Action601
    R&D Progress601
  SL-301 - Drug Profile611
    Product Description611
    Mechanism of Action611
    R&D Progress611
  Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile621
    Product Description621
    Mechanism of Action621
    R&D Progress621
  taladegib - Drug Profile631
    Product Description631
    Mechanism of Action631
    R&D Progress632
  THR-317 - Drug Profile651
    Product Description651
    Mechanism of Action651
    R&D Progress653
  Trilexium - Drug Profile681
    Product Description681
    Mechanism of Action681
    R&D Progress682
  VMY-1103 - Drug Profile701
    Product Description701
    Mechanism of Action701
    R&D Progress701
Medulloblastoma Recent Pipeline Updates7118
Medulloblastoma - Dormant Projects891
Medulloblastoma Product Development Milestones905
  Featured News &Press Releases901
    Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083901
    Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant911
    Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors912
    Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors932
Appendix952
  Methodology951
  Coverage951
  Secondary Research951
  Primary Research951
  Expert Panel Validation951
  Contact Us951
  Disclaimer961

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Medulloblastoma - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Medulloblastoma-Pipeline-Review-H1-2016-2088-15921>
  
APA:
Global Markets Direct - Market Research. (2016). Medulloblastoma - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Medulloblastoma-Pipeline-Review-H1-2016-2088-15921>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.